Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer.

Abstract

BACKGROUND For orientals, titrating doses of docetaxel (60-66 mg/m(2)) have shown equal effectiveness and fewer side effects as a second-line chemotherapy for patients with advanced non-small cell lung cancer (NSCLC). Under such doses, there were no comparative data between classic tri-weekly and Days 1 and 8 weekly schedules. METHODS This Phase II… (More)

Topics

Cite this paper

@article{Lai2005PhaseIR, title={Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer.}, author={Chun-Liang Lai and Chun-Ming Tsai and Chao-Hua Chiu and Gwo-Shu Wang and W. P. Su and Yuh-Min Chen and Reury-Perng Perng}, journal={Japanese journal of clinical oncology}, year={2005}, volume={35 12}, pages={700-6} }